Top 3 Health Care Stocks That May Rocket Higher In December

Several health-care names are trading technically oversold with RSIs at or below ~30 after recent negative stock moves: Larimar Therapeutics (LRMR) reported a wider-than-expected quarterly loss and has slid ~20% over the past month (closed $3.12, down 12.1% on Tuesday; 52-week low $1.61; RSI 29.9). Perrigo (PRGO) reported mixed Q3 results and cut FY25 adjusted EPS guidance below estimates amid softer OTC consumption, shares down ~34% over the month (closed $13.61, down 1.7%; 52-week low $12.17; RSI 29.9). ORIC Pharmaceuticals (ORIC) fell ~16% over the month despite an Evercore ISI Outperform initiation with a $25 PT (closed $10.65, down 4.5%; RSI 29.6). The combination of earnings/guidance weakness, analyst activity and low RSIs suggests technical-driven selling and potential value/trading opportunities, but fundamentals and guidance remain mixed.

Analysis

Market Structure: The flows reflect a rotation out of beaten-up OTC/consumer names and into idiosyncratic biotech risk; PRGO (down ~34% month) is the immediate loser as guidance cut compresses near-term free cash flow and likely widens its credit spread, while retailers/private-label and low-cost generics capture shelf share. LRMR and ORIC see momentum-driven selloffs (RSI ~30) that create high short-term liquidity but leave fundamentals-driven binary outcomes—trial readouts or analyst coverage can re-rate them sharply.

Risk Assessment: Tail risks include clinical readout failures (LRMR/ORIC) or deeper-than-expected consumer demand deterioration and margin erosion at PRGO; probability medium but impact high (equity >50% move). Immediate (days) risks: volatility spikes around earnings/coverage; short-term (weeks–months): RSI mean reversion or guidance revisions; long-term (quarters–years): clinical validation and persistent market-share shifts in OTC channels.

Trade Implications: Favor selective long exposure to ORIC (analyst PT $25 vs $10.65) sized as a tactical 2–3% position with 6–12 month horizon; avoid outright long in PRGO—prefer short or put-spread exposure sized 1–2% given guidance risk. For LRMR use highly constrained speculative stakes (≤0.5–1%) or short-dated OTM calls to play potential binary positive readouts, and hedge portfolio delta with consumer staples defensives if compressions deepen.

Contrarian Angles: Consensus treats RSI<30 as generic buy but misses idiosyncratic fundamentals—PRGO’s share gains imply operational resilience but not immediate EPS recovery; ORIC’s coverage initiation is a directional catalyst not proof of success. Historical parallels (small-cap biotech bounces on coverage) argue for asymmetric options trades (leverage on ORIC vs limited-risk on PRGO) rather than large outright positions.

Key Decisions for Investors

• Establish a tactical 2–3% long position in ORIC (ticker ORIC) with a 6–12 month horizon; supplement with Jan 2026 $12.50 LEAP calls (buy-to-open) sized to equal a 1–1.5% notional exposure and cap cost by selling Jan 2026 $30 calls 1:1 if willing to cap upside.
• Initiate a defensive short/put-spread on PRGO sized 1–2%: buy 3-month 13/10 put spread (debit) or short 1–2% of notional shares with stop-loss at $15.50 (≈+14% from $13.61); target price $10–12 on guidance-driven downside within 3 months.
• Limit exposure to LRMR to ≤0.5–1% as a binary biotech spec: buy 60–90 day 4–6 delta calls or small share lots with hard stop-loss of 30% below entry (roughly $2.2–$2.5) and profit-taking if RSI>50 or share price doubles.
• Pair trade: long ORIC (2%) vs short PRGO (1–2%) to express differential idiosyncratic risk; rebalance monthly and close pair if ORIC misses next major catalyst or PRGO issues new guidance improving EPS visibility.
• Monitor next 30–60 days for three triggers before scaling: ORIC analyst/catalyst calendar and trial readouts, PRGO monthly retail share data and next earnings/guidance, and any FDA/regulatory notices for LRMR; act within 48–72 hours of confirmed catalysts.